These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34222496)

  • 41. Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates.
    Hou Y; Gu XX
    J Immunol; 2003 Apr; 170(8):4373-9. PubMed ID: 12682274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carriage of Haemophilus influenzae in the oropharynx of young children and molecular epidemiology of the isolates after fifteen years of H. influenzae type b vaccination in Italy.
    Giufrè M; Daprai L; Cardines R; Bernaschi P; Ravà L; Accogli M; Raponi M; Garlaschi ML; Ciofi degli Atti ML; Cerquetti M
    Vaccine; 2015 Nov; 33(46):6227-34. PubMed ID: 26440924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The changing epidemiology of invasive Haemophilus influenzae disease: Emergence and global presence of serotype a strains that may require a new vaccine for control.
    Tsang RSW; Ulanova M
    Vaccine; 2017 Jul; 35(33):4270-4275. PubMed ID: 28666758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Fogarty J; Moloney AC; Ramsay ME; Moxon ER
    Pediatr Infect Dis J; 2001 Mar; 20(3):300-5. PubMed ID: 11303834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antisera Against Certain Conserved Surface-Exposed Peptides of Nontypeable Haemophilus influenzae Are Protective.
    Whitby PW; Seale TW; Morton DJ; Stull TL
    PLoS One; 2015; 10(9):e0136867. PubMed ID: 26390432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae.
    Singh S; Wilson JC; Cripps AW; Massa H; Ozberk V; Grice ID; Peak IR
    Vaccine; 2020 Jan; 38(2):309-317. PubMed ID: 31668366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children.
    Khan MN; Kaur R; Pichichero ME
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):439-47. PubMed ID: 22463053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx.
    Kodama S; Hirano T; Noda K; Umemoto S; Suzuki M
    Vaccine; 2011 Feb; 29(10):1881-90. PubMed ID: 21237276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of an important vaccine and diagnostic target in carriage- and disease-related nontypeable Haemophilus influenzae.
    Smith-Vaughan HC; Chang AB; Sarovich DS; Marsh RL; Grimwood K; Leach AJ; Morris PS; Price EP
    Clin Vaccine Immunol; 2014 Feb; 21(2):250-2. PubMed ID: 24285816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae.
    Bertot GM; Becker PD; Guzmán CA; Grinstein S
    J Infect Dis; 2004 Apr; 189(7):1304-12. PubMed ID: 15031801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity.
    McMahon M; Murphy TF; Kyd J; Thanavala Y
    Vaccine; 2005 May; 23(27):3590-6. PubMed ID: 15855018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Passive transfer of antiserum specific for immunogens derived from a nontypeable Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after heterologous challenge.
    Kennedy BJ; Novotny LA; Jurcisek JA; Lobet Y; Bakaletz LO
    Infect Immun; 2000 May; 68(5):2756-65. PubMed ID: 10768970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx.
    Kyd JM; Cripps AW; Novotny LA; Bakaletz LO
    Infect Immun; 2003 Aug; 71(8):4691-9. PubMed ID: 12874350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insights into the population structure and pan-genome of Haemophilus influenzae.
    Pinto M; González-Díaz A; Machado MP; Duarte S; Vieira L; Carriço JA; Marti S; Bajanca-Lavado MP; Gomes JP
    Infect Genet Evol; 2019 Jan; 67():126-135. PubMed ID: 30391557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media.
    Winter LE; Barenkamp SJ
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A P5 peptide that is homologous to peptide 10 of OprF from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae from acutely infected rat lung in the absence of detectable peptide-specific antibody.
    Webb DC; Cripps AW
    Infect Immun; 2000 Jan; 68(1):377-81. PubMed ID: 10603411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and Bacteriologic Analysis of Nontypeable Haemophilus influenzae Strains Isolated from Children with Invasive Diseases in Japan from 2008 to 2015.
    Naito S; Takeuchi N; Ohkusu M; Takahashi-Nakaguchi A; Takahashi H; Imuta N; Nishi J; Shibayama K; Matsuoka M; Sasaki Y; Ishiwada N
    J Clin Microbiol; 2018 Jul; 56(7):. PubMed ID: 29720429
    [No Abstract]   [Full Text] [Related]  

  • 58. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines.
    Forsgren A; Riesbeck K; Janson H
    Clin Infect Dis; 2008 Mar; 46(5):726-31. PubMed ID: 18230042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haemophilus influenzae serotype a as a cause of serious invasive infections.
    Ulanova M; Tsang RSW
    Lancet Infect Dis; 2014 Jan; 14(1):70-82. PubMed ID: 24268829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine.
    Bender JM; Cox CM; Mottice S; She RC; Korgenski K; Daly JA; Pavia AT
    Clin Infect Dis; 2010 Apr; 50(7):e41-6. PubMed ID: 20178414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.